Shaped like a tennis ball, this cancer protein was thought ‘undruggable.’ Amgen found a way to target it
What sets Amgen's small molecule pill apart, even among genetically driven cancer drugs, is the elusiveness of its target: mutant KRAS with structure like a tennis ball.
Scientists have long known that a mutant form of the cell-signaling protein called KRAS causes cancer, but discovering drugs capable of blocking KRAS has proven difficult. The protein is spherical and nearly featureless — its structure has been compared to a tennis ball — leaving potential drugs with few, if any, effective attachment points.
On Wednesday, () is reporting early but potential progress in an effort to block mutant
